Key Points
- CFO Asif Ali sold 8,588 shares on Jan. 20 at an average price of $82.48 for about $708,338, trimming his position by 9.91% to 78,077 shares.
- Protagonist trades with a market cap of $5.24 billion, a PE of 135.31 and a 52‑week range of $33.70–$96.54; last quarter it reported a ($0.62) EPS miss and revenue of $4.71M vs. a $5.41M consensus.
- Analysts have a consensus rating of "Moderate Buy" with an average price target of $86.77 (some targets as high as $115), and institutional investors own 98.63% of the stock.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CFO Asif Ali sold 8,588 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $82.48, for a total value of $708,338.24. Following the transaction, the chief financial officer owned 78,077 shares in the company, valued at $6,439,790.96. The trade was a 9.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Protagonist Therapeutics Stock Performance
Shares of Protagonist Therapeutics stock opened at $83.89 on Thursday. The firm has a 50-day moving average of $86.56 and a 200-day moving average of $71.38. Protagonist Therapeutics, Inc. has a 52-week low of $33.70 and a 52-week high of $96.54. The stock has a market cap of $5.24 billion, a PE ratio of 135.31 and a beta of 2.26.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.03). The business had revenue of $4.71 million for the quarter, compared to the consensus estimate of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. Equities research analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Protagonist Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the business. American Century Companies Inc. lifted its position in shares of Protagonist Therapeutics by 18.7% during the 2nd quarter. American Century Companies Inc. now owns 813,995 shares of the company's stock worth $44,990,000 after buying an additional 128,171 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new position in Protagonist Therapeutics during the second quarter worth about $6,641,000. Voya Investment Management LLC raised its stake in Protagonist Therapeutics by 8.9% during the third quarter. Voya Investment Management LLC now owns 305,419 shares of the company's stock worth $20,289,000 after acquiring an additional 25,065 shares in the last quarter. Nan Fung Trinity HK Ltd. bought a new position in shares of Protagonist Therapeutics in the second quarter worth about $7,464,000. Finally, Creative Planning boosted its stake in shares of Protagonist Therapeutics by 74.3% in the 2nd quarter. Creative Planning now owns 30,204 shares of the company's stock valued at $1,669,000 after purchasing an additional 12,871 shares in the last quarter. Institutional investors own 98.63% of the company's stock.
Analyst Upgrades and Downgrades
PTGX has been the topic of a number of analyst reports. Citigroup increased their price target on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a "buy" rating in a research report on Monday, December 8th. Truist Financial lifted their price objective on Protagonist Therapeutics from $88.00 to $110.00 and gave the company a "buy" rating in a report on Monday, January 5th. BMO Capital Markets reissued an "outperform" rating on shares of Protagonist Therapeutics in a report on Monday, October 13th. JPMorgan Chase & Co. raised their price target on Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an "overweight" rating in a research report on Friday, November 7th. Finally, Johnson Rice set a $112.00 price objective on shares of Protagonist Therapeutics in a research report on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $86.77.
View Our Latest Analysis on PTGX
Protagonist Therapeutics Company Profile
(
Get Free Report)
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
